Upadacitinib As a Novel Treatment for Refractory Eyelid Dermatitis
NCT06684522
·
clinicaltrials.gov ↗
EARLY_PHASE1
Phase
NOT_YET_RECRUITING
Status
10
Enrollment
OTHER
Sponsor class
Conditions
Eyelid Dermatitis
Interventions
DRUG:
Upadacitinib 15 MG
Sponsor
Northwestern University